Jazz Pharmaceuticals JAZZ Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's other non-current liabilities?
- Jazz Pharmaceuticals (JAZZ) reported other non-current liabilities of $161.5M in Q1 2026.
- How has Jazz Pharmaceuticals's other non-current liabilities changed year-over-year?
- Jazz Pharmaceuticals's other non-current liabilities increased by 77.2% year-over-year, from $91.12M to $161.5M.
- What is the long-term trend for Jazz Pharmaceuticals's other non-current liabilities?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's other non-current liabilities has grown at a 4.2% compound annual growth rate (CAGR), from $101.15M to $124.4M.
- What does other non-current liabilities mean?
- Miscellaneous long-term debts or obligations that are not classified as standard debt or pension liabilities.
- How do you interpret other non-current liabilities?
- A significant increase may indicate rising long-term commitments, such as acquisition-related earn-outs or deferred revenue, which warrants further investigation in the footnotes.
- How does other non-current liabilities compare across companies?
- Varies widely by company; high levels in pharma often relate to contingent consideration from M&A activity.